Smith & Nephew Plc Acquisition of Zimmer's Unicondylar Knee in US
June 24 2015 - 12:17PM
RNS Non-Regulatory
TIDMSN.
Smith & Nephew Plc
24 June 2015
Smith & Nephew to acquire Zimmer's Unicondylar Knee system
in US market
24 June 2015
Smith & Nephew (NYSE:SNN; LSE:SN), the global medical
technology business, today announced an agreement to acquire the
Zimmer(R) Unicompartmental High Flex Knee (ZUK) system in the US
market. ZUK is a clinically proven uni knee replacement introduced
globally in 2004. Smith & Nephew has purchased all existing
inventory and certain intellectual property for the US market.
The transaction will close within three business days after the
merger between Zimmer(R) and Biomet(R) has closed.
"Our acquisition of this product line expands our access to a
fast growing segment of the joint reconstruction market," says Brad
Cannon, President of Global Orthopaedic Franchises. "We look
forward to welcoming many new customers to Smith & Nephew and
are excited by this opportunity to demonstrate first-hand our
excellent customer service and broad range of advanced surgical
products."
Terms of the transaction were not disclosed.
Contacts:
Media
Joe Metzger
Smith & Nephew +1 (978) 749-1330
Investor/Analyst
Ingeborg Oie +44 (0)20 7401
Smith & Nephew 7646
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 14,000 employees and a
presence in more than 100 countries. Annual sales in 2013 were more
than $4.3 billion. Smith & Nephew is a member of the FTSE100
(LSE: SN, NYSE: SNN).
For more information about Smith & Nephew, please visit our
corporate website www.smith-nephew.com, follow @SmithNephewplc on
Twitter or visit SmithNephewplc on Facebook.com
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls; litigation relating to patent or other claims;
legal compliance risks and related investigative, remedial or
enforcement actions; strategic actions, including acquisitions and
dispositions, our success in performing due diligence, valuing and
integrating acquired businesses; disruption that may result from
transactions or other changes we make in our business plans or
organisation to adapt to market developments; and numerous other
matters that affect us or our markets, including those of a
political, economic, business, competitive or reputational nature.
Please refer to the documents that Smith & Nephew has filed
with the U.S. Securities and Exchange Commission under the U.S.
Securities Exchange Act of 1934, as amended, including Smith &
Nephew's most recent annual report on Form 20-F, for a discussion
of certain of these factors. Any forward-looking statement is based
on information available to Smith & Nephew as of the date of
the statement. All written or oral forward-looking statements
attributable to Smith & Nephew are qualified by this caution.
Smith & Nephew does not undertake any obligation to update or
revise any forward-looking statement to reflect any change in
circumstances or in Smith & Nephew's expectations.
Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFLRRFISFIE
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Apr 2023 to Apr 2024